© 2017 Beacon Discovery

6118 Nancy Ridge Dr, San Diego 92121

  • LinkedIn Social Icon

June 27, 2018

BEACON DISCOVERY ANNOUNCES PARTNERSHIP WITH ESCIENT PHARMACEUTICALS AND EXPANSION OF ITS SAN DIEGO FACILITY

Beacon Discovery today announced a partnership with Escient Pharmaceuticals. Recently launched with $40 million in Series A financing, Escient leveraged Beacon’s expertise in orphan GPCR drug discovery to validate key data underpinning their development of therapeutics targeting Mas-Related G-Protein Receptors (Mrgpr). Under the terms of the ongoing collaboration, Beacon will support in vitro and in vivo preclinical discovery efforts for Escient’s programs.  “The scientists at Beacon have been invaluable to our launch effort” said Alain Baron, President and CEO of Escient. “we look forward to working closely with Beacon to translate our proprietary insights about the functions and biology of Mrgpr receptors into new medicines”.

 

With the addition of the Escient collaboration, Beacon has expanded its strategic collaborations with leading biotech and large pharma partners to a total of seven. The list of collaborators, all focused on GPCR drug discovery across a variety of therapeutic areas, includes industry leading companies like Boehringer Ingelheim, Takeda and Janssen, as well as small and emerging biopharma organizations.

 

In light of these collaborations, Beacon is expanding its facilities to support both the ongoing strategic partnerships in addition to the development of proprietary internal programs. ”We are delighted with the progress we’ve made in the last two years. In addition to these collaborations with key scientific and industry partners, we are now in a position to accelerate our own internal programs.” said Sunny Al-Shamma, President and CEO of Beacon.

 

About Beacon

Founded in 2016 and headquartered in San Diego, Beacon Discovery is a world leader in all facets of GPCR-focused drug discovery.  Beacon’s mission is to efficiently identify and advance molecules targeting GPCRs from concept to clinic.  Beacon’s internal pipeline focusses on GPCRs for which the native ligand remains unknown. These orphan GPCRs provide unexploited opportunities to develop novel drugs addressing significant unmet medical need. In addition, Beacon collaborates with biopharma partners to leverage internally enabled GPCR targets and small molecule modulators as well as its wealth of GPCR discovery skills and tools.

For more information, please contact:  Sunny Al-Shamma, CEO, haa@beacondiscovery.com

May 09, 2018

BEACON DISCOVERY ANNOUNCES COLLABORATION WITH OUTPOST MEDICINE

Beacon Discovery is happy to announce their collaboration with Outpost Medicine.  As a pre-clinical pharmacology expert team, Beacon played a key role in the evaluation of an undisclosed preclinical compound, facilitating the recent licensing agreement between Arena Pharmaceuticals and Outpost Medicine. Outpost will now further advance the compound that has potential utility in treating genitourinary disorders.

 

During their time at Arena, senior Beacon scientists were responsible for leading the discovery and early evaluation of this unique compound and so are particularly pleased to assist in its ongoing development in order to realize its potential as a therapeutic agent. Having key knowledge and expertise around both the licensed compound and its receptor, the Beacon team will continue to work in partnership with Outpost on additional aspects to evaluate the pharmacology and therapeutic potential of this novel compound as they strive to bring an important new treatment to patients.

February 27, 2018

BEACON DISCOVERY ANNOUNCES MULTI-YEAR GPCR DRUG DISCOVERY COLLABORATION WITH TAKEDA FOCUSED ON GASTROINTESTINAL DISORDERS

Beacon Discovery today announced the formation of a multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited focused on a number of G-protein coupled receptors (GPCRs) that play an important role in the pathology of gastrointestinal disorders.

Through the collaboration, Beacon will leverage its GPCR drug discovery expertise to identify drug candidates for a range of GI diseases with significant unmet medical need.  “This collaboration represents another exciting milestone in the development of key strategic alliances for Beacon”, said Sunny Al-Shamma, Beacon’s CEO. “Takeda’s world class R&D organization and outstanding disease area expertise will help us realize our goal to discover first-in-class medicines”.

The agreement grants Takeda worldwide rights to develop, manufacture and commercialize products resulting from the collaboration. In exchange, Beacon will receive an upfront payment, research support, and is eligible to receive milestone payments as well as royalties on future sales of such products.

 

About Beacon

Founded in 2016 and headquartered in San Diego, California, Beacon Discovery is a privately held company that is a world leader in all facets of GPCR-focused drug discovery.  Beacon’s mission is to efficiently identify and advance molecules targeting GPCRs from concept to clinic.  Beacon collaborates with biopharma partners to leverage internally enabled GPCR targets and small molecule modulators as well as its wealth of GPCR discovery skills and tools.  In addition to Takeda, Beacon has established key strategic partnerships with Boehringer Ingelheim, Janssen, and multiple start-up companies.  Beacon also has a number of internal programs focused on therapeutically important targets to address unmet medical needs.

 

About GPCRs

GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Close to 30% of marketed drugs target this receptor family. GPCR research has expanded in recent years from traditional orthosteric receptor-ligand interactions to encompass new approaches based on signaling via beta-arrestin, biased ligands, allosteric ligands, and persistent signaling. In addition, the revolution in GPCR structural biology has enabled significant advances in both biophysical methods and computational modeling of receptors which can aid in the design of new molecules to target these receptors.

 

For more information, please contact:  Sunny Al-Shamma, CEO, haa@beacondiscovery.com

January 31, 2018

ELSEVIER WELCOMES SIX BIOTECH AND PHARMA START-UPS THE HIVE, SUPPORTING THE MOST CUTTING-EDGE RESEARCH IN INDUSTRY

Start-ups working on a range of technologies and discoveries – from AI to immunotherapy – receive complimentary access to Elsevier’s information solutions to accelerate innovation

Elsevier, the global information analytics business specializing in science and health, today announced that six start-up companies have been selected from more than 150 global applicants for The Hive, Elsevier’s innovation initiative for biotech and pharmaceutical start-ups.

January 04, 2018

BEACON DISCOVERY ANNOUNCES MULTI-YEAR GPCR-FOCUSED DRUG DISCOVERY COLLABORATION WITH JANSSEN PHARMACEUTICALS

Beacon Discovery, a leading drug discovery company focused on G-Protein Coupled Receptor (GPCR) research, today announced it has entered into a collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen). Under the terms of the agreement, Beacon and Janssen will focus on the discovery and development of small molecule compounds for multiple undisclosed GPCR targets for the treatment of metabolic diseases. 
 

Through the collaboration, the companies will conduct research to identify drug candidates for the treatment of obesity and other metabolic diseases where significant unmet medical need exists.  “We are delighted to be part of this strategic discovery collaboration which realizes our vision to combine our GPCR drug discovery expertise with the therapeutic area strengths and development capabilities of Janssen and our other corporate partners,” said Sunny Al-Shamma, Beacon’s CEO. 
 

The agreement grants Janssen an option to exercise and obtain worldwide rights to develop, manufacture and commercialize products resulting from the collaboration. In exchange, Beacon will receive an upfront payment, and if the option is exercised, milestones and royalties on future sales of such products.

September 14, 2017

BEACON DISCOVERY CELEBRATES FIRST ANNIVERSARY AND ANNOUNCES COLLABORATIONS WITH TWO SAN DIEGO START-UPS

Since its launch in September last year, Beacon has been consolidating its drug discovery operations and advancing a number of internal drug discovery programs. Beacon is developing alliances with local, national and international partners. As a first step in this process we are delighted to announce the initiation of research collaborations on GPCR targets with two San Diego startups. One of these start-ups is Pipeline Therapeutics.

September 07, 2016

BEACON DISCOVERY INC., LAUNCHES AS NEW GPCR-FOCUSED DRUG DISCOVERY INCUBATOR

Experienced team to capitalize on breakthroughs in GPCR biology to drive internal and partnered drug discovery efforts

San Diego, CA- Beacon Discovery Inc. is a newly launched, privately held drug discovery incubator that will efficiently identify and advance molecules targeting G-Protein Coupled Receptors (GPCRs) from concept to clinic. The founders of Beacon have a wealth of diverse experience in GPCR drug discovery and have delivered more than 20 compounds into clinical development during their careers. The team will utilize this unique multidisciplinary expertise along with state-of-the-art technologies to capitalize on recent advances in GPCR pharmacology.

1 / 1

Please reload

News